Viewing Study NCT00345579



Ignite Creation Date: 2024-05-05 @ 4:56 PM
Last Modification Date: 2024-10-26 @ 9:25 AM
Study NCT ID: NCT00345579
Status: COMPLETED
Last Update Posted: 2016-12-16
First Post: 2006-06-26

Brief Title: Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine Given at 2 4 6 and 12 to 15 Months of Age
Sponsor: GlaxoSmithKline
Organization: GlaxoSmithKline

Study Overview

Official Title: A Single-blind Randomized Controlled Multinational Study for the Evaluation of Safety of GlaxoSmithKline GSK Biologicals Investigational Vaccination Regimen Compared to Monovalent Haemophilus Influenzae Type b Hib Control Vaccine in Healthy Infants at 2 4 6 and 12 to 15 Months of Age
Status: COMPLETED
Status Verified Date: 2016-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary phase of this study is evaluating the safety of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine when each are co-administered with Pediarix to healthy infants at 2 4 and 6 months of age

This protocol posting deals with objectives outcome measures of the primary phase of the study The objectives outcome measures of the Booster phase are presented in a separate protocol posting NCT number 00345683

The Protocol Posting has been updated in order to comply with the FDA Amendment Act Sep 2007
Detailed Description: PediarixInfanrix Penta and Prevnar should be co-administered to all subjects in all study groups according to a 2 4 and 6 month schedule concomitantly with study vaccines

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None